Serum levels of sestrin 2 in patients with sarcoidosis

A. Roussou, A. Papaioannou, E. Manali, A. Spathis, N. Pianou, A. Georgakopoulos, J. Tomos, A. Karakatsani, K. Kostikas, S. Chatziioannou, P. Karakitsos, S. Papiris (Athens, Greece)

Source: International Congress 2014 – ILDs 6
Session: ILDs 6
Session type: Thematic Poster Session
Number: 3797
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Abstract

Introduction:Oxidative stress is involved in pathogenesis of Sarcoidosis. Sestrins are proteins with antioxidative capacity that accumulate in cells exposed to oxidative stress. The aim of our study was to test whether serum sestrin 2 (Ses2) levels in patients with sarcoidosis are related to disease extent, to the involvement of specific organs and to treatment with corticosteroidsMethods:Serum samples were collected from consecutive patients with sarcoidosis. Patients underwent pulmonary function tests, chest X-ray, HRCT and Positron Emission Tomography (PET). Patients with involvement of 3 or more organs were considered to have extended disease. Serum Ses2 levels were measured with ELISAResults:35 patients (22 female) (mean age 54.0±14.4 years) were included in the study. Serum Se2 levels were higher in patients with limited disease compared to patients with extended disease [median(IQR) 3.19(1.61, 7.72) vs 0.89(0.68, 2.66)ng/mL, respectively p=0.009. Steroid naive patients with limited disease had higher serum Ses2 levels compared to those with extended disease [3.27(1.62, 18.19) vs 0.94(0.81, 2.17) respectively, p=0.024]. However, serum Ses2 levels were not related to disease extend in patients receiving corticosteroids [3.39(1.14, 6.16) vs 0.79(0.53, 5.09) for limited and extended disease respectively p=0.159]. Serum Ses2 levels were higher in patients with no node involvement compared to patients with any node involvement [4.96(1.63, 18.19) vs 1.88(0.88, 3.19) respectively p=0.036]Conclusion:Serum Ses2 levels are lower in patients with extended sarcoidosis and those with node involvement. Corticosteroids seem to affect serum Ses2 levels. The possible antioxidative role of Ses2 in sarcoidosis has to be further evaluated.


Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Roussou, A. Papaioannou, E. Manali, A. Spathis, N. Pianou, A. Georgakopoulos, J. Tomos, A. Karakatsani, K. Kostikas, S. Chatziioannou, P. Karakitsos, S. Papiris (Athens, Greece). Serum levels of sestrin 2 in patients with sarcoidosis. Eur Respir J 2014; 44: Suppl. 58, 3797

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Extrapulmonary involvement in sarcoidosis patients
Source: International Congress 2014 – ILDs 4
Year: 2014


Assessing sarcoidosis activity: Is serum chitotriosidase a reliable marker? Study of 430 patients and 264 healthy controls
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014

Atypical variants of clinical course of sarcoidosis
Source: International Congress 2014 – ILDs 6
Year: 2014

Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients
Source: International Congress 2014 – Sarcoidosis
Year: 2014

Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014

Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 5
Year: 2014

Mutation alone does not predict the clinical course of surfactant protein C deficiency in children
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014

Serum procalcitonin is useful in differentiating between drug-induced pneumonitis and bacterial pneumonia
Source: International Congress 2014 – ILDs 5
Year: 2014


European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014

Predictors of cardiovascular events in newly diagnosed patients with sarcoidosis
Source: International Congress 2014 – Sarcoidosis
Year: 2014

Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014

Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: International Congress 2014 – IPF and surroundings
Year: 2014



Neuroendocrine cell hyperplasia (NEHI) and NEHI Syndrome: Lung biopsy necessary?
Source: International Congress 2014 – ILDs 4
Year: 2014


Reduction in disease progression with nintedanib in the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients?
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014

The role of CCR2+CD4+T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014

Cryptogenic organising pneumonia focusing on its prognostic determinants
Source: International Congress 2014 – ILDs 4
Year: 2014


Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Beneficial effect of azithromycin in children with diffuse parenchymal lung disease
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014